免疫揭秘:治疗帕金森氏症的翻译网络-免疫公园网。

Open research Europe Pub Date : 2025-01-23 eCollection Date: 2024-01-01 DOI:10.12688/openreseurope.17547.2
Mitilda Gugu, Shubhra Acharya, Dogukan Pira, Simona Poletti, Alessia di Flora, Tamara Saksida, Vladimirs Pilipenko, Marina Romero-Ramos, Franca Marino, Laura Muñoz Delgado, Neda Nikolovski, Yasemin Gursoy Ozdemir, Dale Lawson, Cristoforo Comi, Inês Figueira
{"title":"免疫揭秘:治疗帕金森氏症的翻译网络-免疫公园网。","authors":"Mitilda Gugu, Shubhra Acharya, Dogukan Pira, Simona Poletti, Alessia di Flora, Tamara Saksida, Vladimirs Pilipenko, Marina Romero-Ramos, Franca Marino, Laura Muñoz Delgado, Neda Nikolovski, Yasemin Gursoy Ozdemir, Dale Lawson, Cristoforo Comi, Inês Figueira","doi":"10.12688/openreseurope.17547.2","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network - IMMUPARKNET (The role of IMMUnity in tackling PARKinson's disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.</p>","PeriodicalId":74359,"journal":{"name":"Open research Europe","volume":"4 ","pages":"119"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795026/pdf/","citationCount":"0","resultStr":"{\"title\":\"IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease - IMMUPARKNET.\",\"authors\":\"Mitilda Gugu, Shubhra Acharya, Dogukan Pira, Simona Poletti, Alessia di Flora, Tamara Saksida, Vladimirs Pilipenko, Marina Romero-Ramos, Franca Marino, Laura Muñoz Delgado, Neda Nikolovski, Yasemin Gursoy Ozdemir, Dale Lawson, Cristoforo Comi, Inês Figueira\",\"doi\":\"10.12688/openreseurope.17547.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Parkinson's disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network - IMMUPARKNET (The role of IMMUnity in tackling PARKinson's disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.</p>\",\"PeriodicalId\":74359,\"journal\":{\"name\":\"Open research Europe\",\"volume\":\"4 \",\"pages\":\"119\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795026/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open research Europe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/openreseurope.17547.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open research Europe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/openreseurope.17547.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

帕金森氏症(PD)影响了欧盟100多万人。目前还没有明确的治疗方法,这意味着患者只能依靠对症治疗,而对症治疗本身就有副作用。因此,患者、护理人员和卫生工作者都强烈感到需要在知识和现有治疗方面取得进步。这一未被满足的需求激发了通过一个共同网络——IMMUPARKNET(通过翻译网络免疫在治疗帕金森病中的作用)协调合作努力的想法。IMMUPARKNET成本行动关注PD的挑战及其与免疫应答的相关串扰。尽管免疫在帕金森病的发生和发展中的作用已被广泛认识,但仍不清楚。IMMUPARKNET的主要目标是通过建立一个创新的跨学科研究网络和促进来自不同国家和机构的专家之间的专门知识交流来填补这一知识差距。当我们聚集研究PD及相关领域免疫的科学家和临床医生时,IMMUPARKNET将建立一个多学科生态系统的第一个核心,旨在协调研究和临床实践中的努力和方法,以促进PD突破性治疗的发展。通过会议、培训学校、网络研讨会、立场文件和审查手稿,IMMUPARKNET将在该领域的专家之间进行富有成效的知识交流。免疫公园网的结构围绕5个工作组展开,共有来自34个不同国家的157名活跃成员。在这些活跃成员中,58.5%是年轻的研究人员,而67.5%来自包容性目标国家(ITC -研究密集程度较低的COST成员;https://www.cost.eu/about/members/)。IMMUPARKNET的成果将促进研究资源的共享和发展,为新的治疗方法铺平道路,并确定现有的治疗方法可以重新利用的地方,最终并有希望找到治疗帕金森病的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease - IMMUPARKNET.

Parkinson's disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network - IMMUPARKNET (The role of IMMUnity in tackling PARKinson's disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信